Plain-English translation of NCT06649110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called LTP001 that may help treat pulmonary arterial hypertension, a serious condition where blood vessels in the lungs become narrow and stiff. The trial has two parts: first, researchers will give LTP001 to healthy volunteers to make sure it is safe and to understand how the body processes it. Then, they will test the medication in people who have been diagnosed with pulmonary arterial hypertension to see if it improves their ability to exercise and breathe.
Pulmonary arterial hypertension is a rare but serious disease that makes it hard for the heart to pump blood through the lungs, and current treatments do not work well enough for everyone. This trial aims to see if the medication can help people with this condition live better lives.
You likely qualify if…
You likely don't qualify if…
If you join the first part of the study, you will visit the research center to receive different doses of the medication or a placebo (a dummy pill with no active ingredient), and researchers will monitor you for safety and take blood samples to see how your body processes the medication. If you qualify for the second part with pulmonary arterial hypertension, you will take the medication along with your regular PAH treatments and return for visits to have your symptoms, exercise ability, and heart function checked. The study includes a safety follow-up period after you stop taking the medication.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States